This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB09010/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB09010/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://www.drugs.com/international/

Statements

Subject Item
n2:DB09010
rdf:type
n3:Drug
n3:description
Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.
n3:group
withdrawn
owl:sameAs
n6:DB09010
dcterms:title
Carmofur
adms:identifier
n9:DB09010 n10:Carmofur
n3:synthesisReference
U.S. Patent 4,071,519.
foaf:page
n12:carmofur.html
n3:IUPAC-Name
n4:271B649F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B64A5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B64A4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B64A1-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B64A2-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B64A3-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B649D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B649B-363D-11E5-9242-09173F13E4C5 n4:271B649E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B649C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B64AB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B64AC-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B64A6-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B64A7-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B64A9-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B64A8-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B64AA-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
61422-45-5
n3:Bioavailability
n4:271B64B1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B64B3-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B64B4-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B64B5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B64B0-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B64AF-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B64B2-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B64A0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B64AD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B64AE-363D-11E5-9242-09173F13E4C5